WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Detailed price information for Prelude Therapeutics Inc (PRLD-Q) from The Globe and Mail including charting and trades.

Analyst Reni Benjamin from JMP Securities reiterated a Buy rating on Prelude Therapeutics (PRLD – Research Report) and keeping the price ...

Prelude Therapeutics Inc (PRLD)股票已达到52周低点，交易价格为1.32美元，这家生物制药公司正面临着充满挑战的市场环境。这一最新价格水平反映出与之前时期相比的显著下跌，对投资者和利益相关者来说标志着一个令人担忧的里程碑。在过去一年中，PRLD的价值下降了21.01%，表明公司的增长前景面临着看跌情绪和潜在的不利因素。52周低点作为公司表现的关键指标，可能会促使公司重 ...

Prelude Therapeutics ( (PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD) has unveiled encouraging results from its ongoing Phase 1 trial of PRT3789, ...

On Thursday, Prelude Therapeutics Inc (PRLD) stock saw a decline, ending the day at $1.2 which represents a decrease of $-0.12 or -9.09% from the prior close of $1.32. The stock opened at $1.31 and ...

PRLD stock touches 52-week low at $1.32 amid market challenges Prelude Therapeutics Inc (PRLD) stock has reached a 52-week low, trading at $1.32, as the biopharmaceutical company faces a ...

Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics (PRLD) to $1 from $3 and keeps an Underweight rating on the shares. The updated SMARCA2 degrader data show ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision oncology therapies, finds itself at a critical juncture as it approaches several ...

– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC) – First safety data presented from ...